batefenterol (GSK961081) / GSK  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
batefenterol (GSK961081) / GSK
NCT00478738 / 2006-006240-63: A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients

Completed
2
82
Europe, RoW
GSK961081
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
05/08
05/08
NCT00674817 / 2008-000725-18: An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.

Completed
2
45
Europe, RoW
400 microgrammes GSK961081, 1200 microgrammes GSK961081
Theravance Biopharma, GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
10/08
10/08
NCT01319019: A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
2
437
Europe, RoW
GSK961081, Salmeterol, Placebo
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
09/11
09/11
2010-022796-62: A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.

Completed
2
425
Europe
GSK961081, Salmeterol 50mcg, GSK961081, Inhalation powder, Serevent™ Diskus 50 microgram
GlaxoSmithKline Research & Development Ltd
Chronic Obstructive Pulmonary Disease
 
 
NCT02573870: Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Completed
2
63
US
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
07/16
07/16
NCT02570165 / 2015-001409-15: Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
2
325
Europe, US, RoW
Batefenterol, Umeclidinium/ Vilanterol, Placebo
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
07/16
07/16

Download Options